EVIO

EVIO Net Debt / EBITDA

The Net Debt to EBITDA of EVIO (EVIO) as of Nov 7, 2026 is -5.61. In the previous year, Net Debt to EBITDA was -3.40 — a change of 64.75% (lower).

Net Debt / EBITDA

-5.61

YoY

64.75%

Last updated:

Net Debt to EBITDA of EVIO is 2022 -5.61 . Net Debt to EBITDA of EVIO was 2021 -3.40 . It decreases by 64.75% lower compared to the previous year.

The EVIO Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2015
-0.01 USD
Jan 1, 2016
-0.38 USD
Jan 1, 2017
-2.28 USD
Jan 1, 2018
-0.76 USD
Jan 1, 2019
-0.86 USD
Jan 1, 2020
-3.59 USD
Jan 1, 2021
-3.40 USD
Jan 1, 2022
-5.61 USD
The EVIO Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
-5.61+64.75%
-3.40-5.10%
-3.59+317.37%
-0.86+12.68%
-0.76-66.57%
-2.28+497.24%
-0.38+3,820.29%
-0.01-37.32%
-0.02—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

EVIO Stock analysis

What does EVIO do? EVIO, Inc. generates revenue through analytical testing services for cannabis and hemp products, targeting agricultural and pharmaceutical industries. The company operates subsidiaries including Smith Scientific Industries, LLC, Greenhaus Analytical Labs, LLC, and Viridis Analytics, LLC, which provide testing to verify regulatory compliance for product sales. Residential and commercial construction services form another revenue stream, while research and development and consulting services cater to cannabis and hemp industry participants. Subsidiaries such as EVIO Labs OR, Inc., C3 Labs, LLC, and EVIO Labs Humboldt, LLC further support the company's service offerings. The primary customers for EVIO's testing services are businesses within the cannabis and hemp sectors requiring regulatory verification. Construction services are sold to residential and commercial clients, while R&D and consulting services target industry participants seeking expertise. Subsidiaries like Keystone Labs, Inc. contribute to the analytical testing segment, ensuring compliance with market requirements. EVIO's revenue model relies on multiple service lines across different industry segments without relying on external partnerships or third-party platforms. EVIO's service portfolio includes analytical testing, construction, and consulting, with all operations managed through its subsidiaries. The company's focus on regulatory compliance for cannabis and hemp products drives demand for its testing services. Construction services provide additional revenue, while R&D and consulting support industry growth. Subsidiaries such as Smith Scientific Industries, LLC and Greenhaus Analytical Labs, LLC operate under the EVIO brand to deliver specialized services to clients in the agricultural and pharmaceutical sectors. EVIO is one of the most popular companies on Eulerpool.

Frequently Asked Questions about EVIO stock

Net Debt to EBITDA of EVIO is -5.61 in 2022.

Net Debt to EBITDA of EVIO changed from -3.40 to -5.61, representing a 64.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA EVIO since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's EVIO with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — EVIO

All Key Metrics — EVIO